Mengyuan Li

1095 Jie Fang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia.

Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia.

Journal: iScience

Published: August 21, 2025

DIA Regimen Versus IA Regimen for Induction Therapy in Younger Adults With Acute Myeloid Leukemia: A Multicenter Open-Label Randomized Controlled Trial.

DIA Regimen Versus IA Regimen for Induction Therapy in Younger Adults With Acute Myeloid Leukemia: A Multicenter Open-Label Randomized Controlled Trial.

Journal: American journal of hematology

Published: July 12, 2025

Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.

Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.

Journal: Transplantation and cellular therapy

Published: April 07, 2025

Retraction Note: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

Retraction Note: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

Journal: Clinical epigenetics

Published: August 01, 2024

The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.

Journal: Clinical epigenetics

Published: November 02, 2023

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma.

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma.

Journal: Frontiers in pharmacology

Published: May 05, 2023

Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Journal: International journal of cancer

Published: August 04, 2022

DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation.

DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation.

Journal: Annals of medicine

Published: July 15, 2022

Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia.

Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 18, 2021

Novel spontaneous myelodysplastic syndrome mouse model.

Novel spontaneous myelodysplastic syndrome mouse model.

Journal: Animal models and experimental medicine

Published: November 27, 2020

Summary of animal models of myelodysplastic syndrome.

Summary of animal models of myelodysplastic syndrome.

Journal: Animal models and experimental medicine

Published: August 28, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026